ANI Pharmaceuticals (ANIP) Stock Price & Analysis
Score
AI Analysis
SnapshotANI Pharmaceuticals mixes growth with a still-reasonable multiple — Growth 76/100 with P/E 13.0, about 78% below its own multi-year median. Under the hood: P/E 13.0, about 78% below its own multi-year median, plus revenue compounding ~41% annually over recent years. Street targets still imply ~39% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
ANI Pharmaceuticals, Inc. (ANIP) last printed $71.44. Equity value is $1.62B. Trailing earnings multiple 12.97. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $128.62M | $176.84M | $201.58M | $206.55M | $208.47M | $216.14M | $316.38M | $486.82M | $614.38M | $883.37M |
About
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.